fluticasone / Generic mfg. - LARVOL DELTA

Eosinophilic Esophagitis Revealed by Hematemesis in an Asthmatic Adolescent: A Case Report. (PubMed, Cureus) - "Treatment with oral fluticasone (250 μg twice daily) combined with double-dose proton pump inhibitors resulted in rapid clinical remission and complete histological normalization at 10 months. This case highlights the need to systematically consider EoE in the presence of any acute gastrointestinal symptoms in a patient with atopic predisposition, and the importance of early management."

Journal • Acute Respiratory Distress Syndrome • Allergy • Asthma • Cardiovascular • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology • Pulmonary Disease • Respiratory Diseases

Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA) (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: Eurofarma Laboratorios S.A. | N=174 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Head-to-Head • Trial withdrawal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Dose-Response and Time-Course Dynamics of Biologics in Eosinophilic Esophagitis: A Model-Based Network Meta-Analysis (ACG 2026) - "Sixteen trial arms across seven classes (dupilumab, cendakimab, mepolizumab, budesonide orodispersible tablet, fluticasone, proton pump inhibitors, and reslizumab) were analyzed. Dupilumab dose-response modeling revealed Emax 88.6%, ED50 1.0 mg, and γ 0.10, indicating near-maximal efficacy at clinical doses with limited gain beyond 100 mg. Increasing from 100 to 300 mg added only 2.3% additional response. Time-course modeling (300 mg weekly) estimated ET50 17.8 weeks, with predicted remission rates of 36% (week 8), 45% (week 12), 62% (week 24), and 80% (week 52), closely matching observed trial data (week 24: 59-60%; week 52: 84.6%)."

Retrospective data • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology

The Prognostic Impact of Inhaled Corticosteroid Type in Advanced COPD Patients on LTOT Hospitalized for Community-Acquired Pneumonia (ERS 2026) - "Methods Patients with COPD on LTOT, hospitalized for pneumonia and treated with either fluticasone- or budesonide- containing ICS over a two-year period (2024-2025) were included (n = 116)...Conclusion In advanced COPD patients on LTOT hospitalized with CAP, ICS type was not associated with short- or long-term mortality, suggesting no significant impact on prognosis in this high-risk population. These findings add to the limited evidence available in this specific subgroup and warrant confirmation in larger prospective studies."

Clinical • Metastases • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pneumonia • Respiratory Diseases • CRP

Role of Oscillometry and Therapeutic response to Fluticasone/Vilanterol in pre COPD: A randomized, double blind, placebo controlled trial (ERS 2026) - "Subjects with Pre COPD defined as AX>6 cmH2O/L.s when treated with FF/V showed significant improvements in CAT score and lung elastance measured by AX."

Clinical • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

"FeNO suppression testing in pediatric severe asthma: identifying non-adherence and corticosteroid resistance" (ERS 2026) - "Patients received 1000 µg/day of inhaled fluticasone for 7 days in addition to usual treatment, with remote monitoring... The FST identified non-adherence and corticosteroid insufficient treatment or resistance in SA, enabling treatment optimization."

Adherence • Clinical • Asthma • Immunology • Pediatrics • Respiratory Diseases

FeNO suppression test in Children with Severe Asthma (ERS 2026) - " Children with SA (requiring high dose of inhaled steroids plus LABA and/or montelukast) with two or more consecutive measurements of elevated FENO (the last at the moment of inclusion)...FST: Children underwent a week of treatment with fluticasone 500 mcg twice a day (MDI with spacer, single inhalation and retention technique) under remote supervision (WhatsApp); on day 8, they repeated FENO measurement and all evaluations... Most of our children with SA and high FENO had a negative FST."

Clinical • Asthma • Immunology • Respiratory Diseases

POST-INFECTIOUS BRONCHIOLITIS OBLITERANS CASES – CLINICAL DATA ANALYSIS (ERS 2026) - "All patients received inhaled fluticasone, montelukast daily, and azithromycin three times a week. After six months of treatment, symptoms resolved in 86,7% of the cases. Conclusion Diagnosis and treatment durations in PIBO can be variable and immunodeficiency can affect clinical presentation and timing of diagnosis."

Clinical data • CNS Disorders • Diabetes • Osteoporosis • Pulmonary Disease • Respiratory Diseases • Sleep Disorder

A prospective, observational, real-world analysis of the effects of different as-needed low-dose inhaled corticosteroid–formoterol combinations in asthma control (ERS 2026) - "Objective:Global Initiative for Asthma steps 1-2 combined,asthma treatments include as-needed low-dose inhaled corticosteroids-formoterol.However,the comparative effectiveness of different ICS–formoterol combinations beyond budesonide remains underexplored in real-world settings.To explore the differences between different ICS treatments in patients with asthma, we determined asthma control,fractional exhaled nitric oxide levels,and the results of pulmonary function tests over 6 months using real-world combinations of budesonide-formoterol,beclomethasone-formoterol,fluticasone-formoterol and mometasone-formoterol. As-needed low-dose ICS–formoterol combinations as anti-inflammatory reliever alone ensure effective asthma control and maintain normal FeNO and FEV1 levels."

Clinical • Observational data • Real-world • Real-world evidence • Asthma • Immunology • Respiratory Diseases

Frequency and Clinical Relevance of Residual Bronchodilator Response in Adults with Asthma (ERS 2026) - " We included 250 patients (Mean age 51 ± 14 y; 56% female; 58% severe; FEV₁ 78 ± 22% pred.; fluticasone eq... A positive residual BDR is frequent and clinically relevant in asthma patients on inhaled maintenance therapy."

Clinical • Asthma • Immunology • Inflammation • Respiratory Diseases

EFFECTIVENESS OF COMBINATIONS OF FLUTICASONE/FORMOTEROL VS BUDESONIDE/FORMOTEROL IN PATIENTS OF MILD TO MODERATE BRONCHIAL ASTHMA: A SYSTEMATIC REVIEW AND META-ANALYSIS (CHEST 2026) - No abstract available

Retrospective data • Review • Asthma • Immunology • Respiratory Diseases

Trends in the Use and Costs of Medications for Respiratory Management Included in the 2022 Benefit Plan of the Colombia Health System. (PubMed, Drugs Real World Outcomes) - "After the 2022 Benefit Plan update for respiratory conditions such as asthma and chronic obstructive pulmonary disease, increases in the dispensing and direct pharmaceutical costs of the newly included therapies were observed. These temporal changes suggest modifications in prescribing and dispensing patterns, potentially reflecting greater access to recommended first-line therapies, although causal attributions to the Benefit Plan update cannot be established, given the descriptive nature of this study."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Comparing Pneumonia Risks of Budesonide with Fluticasone Among Patients with Asthma in Hong Kong: A Territory-Wide Retrospective Study. (PubMed, Adv Ther) - "There was no significant difference in pneumonia risks for BUD and fluticasone (FF/FP) among patients with moderate to severe asthma."

Journal • Retrospective data • Asthma • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Medium-Dose Compared With High-Dose Inhaled Corticosteroids in Combination Triple Inhaler Therapy for Asthma: A Systematic Review and Meta-Analysis. (PubMed, CHEST Pulm) - "Three randomized controlled trials (N = 3,804) were identified, comparing MD and HD ICS/LABA/LAMA containing fluticasone or mometasone...At both the individual and population level, the use of HD ICS/LABA/LAMA needs to be considered alongside the potential systemic side effects. PROSPERO Registry; No.: CRD42025634340; URL: https://www.crd.york.ac.uk/prospero/."

Journal • Retrospective data • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Exhalation Delivery System with Fluticasone in Chronic Rhinosinusitis by Eosinophil, Asthma, and Allergy Status. (PubMed, Ann Allergy Asthma Immunol) - P3 | "These results support EDS-FLU as an effective treatment for CRS, independent of underlying inflammatory endotype or common comorbid conditions. Due to the limitations of this analysis, further investigation is warranted."

Journal • Allergy • Asthma • Eosinophilia • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis

Azelastine-Fluticasone Intranasal Combination Therapy in Otorhinolaryngology: Clinical Evidence, Current Practice Patterns and Future Perspectives. (PubMed, Clin Otolaryngol) - "Azelastine-fluticasone combination therapy represents an evidence-based, guideline-recommended option for moderate-to-severe AR in ENT practice. Its dual mechanism, rapid onset, favourable safety profile and high patient acceptability support its integration into contemporary treatment algorithms, particularly for patients requiring enhanced symptom control beyond monotherapy. The combination represents a meaningful therapeutic advancement, and further research is needed to fully characterise its role in perennial AR management."

Journal • Allergic Rhinitis • Immunology • Inflammation • Otorhinolaryngology

Effects of the Direct Interaction Between Streptococcus Salivarius 24SMBc and Streptococcus Oralis 89a and the Respiratory Epithelium in Children (clinicaltrials.gov) - P3 | N=60 | Completed | Sponsor: Federico II University | Unknown status ➔ Completed

Trial completion • Allergy • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology

Real-World Comparison of Dupilumab and Swallowed Topical Corticosteroids for the Prevention of Esophageal Dilation and Food Impaction in Eosinophilic Esophagitis (ACG 2026) - "The average age at initiation was 39 years for Dupilumab, 42 years for Budesonide, and 45 years for Fluticasone. Cumulative 36-month dilation rates were similar across groups, occurring in 13.6% of Dupilumab patients and 13.9% of Fluticasone patients. However, Dupilumab patients required more frequent dilations within the first 6 months of therapy (8.0% versus 6.1%), likely reflecting channeling bias where biologics are initiated in patients with higher baseline fibrotic disease severity."

Clinical • Real-world • Real-world evidence • Eosinophilic Esophagitis • Fibrosis • Gastrointestinal Disorder • Immunology

Comparative Efficacy and Safety of Pharmacological Therapies for Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis (ACG 2026) - "For dysphagia reduction, dupilumab ranked highest (P-score 0.952; MD â12.60, 95% CI â17.05 to â8.15) and was the only treatment to achieve a statistically significant head-to-head advantage over a comparator. Across efficacy outcomes, the or dispersible budesonide tablet (BOT 1 mg BID) demonstrated consistent superiority. For histological remission, BOT ranked first by P-score (0.785) with a statistically significant benefit over placebo (RR 55.03, 95% CI 3.52 to 860.06), alongside budesonide oral suspension and MDI fluticasone. BOT also led in clinical remission (RR 4.30, 95% CI 1.69 to 10.95; P-score 0.958) and complete symptom resolution (RR 2.67, 95% CI 1.36 to 5.23; P-score 0.888)."

Retrospective data • Review • Candidiasis • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology

Esophageal Lichen Planus With an Esophageal Stricture: A Rare Lichen Planus Manifestation (ACG 2026) - "Management included omeprazole for 8 weeks and swallowed fluticasone for 4 weeks...Drug-induced etiology was considered, as the patient was taking possible causative medications including etanercept and lisinopril...ELP remains underdiagnosed due to variable presentation and subtle endoscopic findings, our case highlights the need for increased vigilance in selected populations. Figure: Figure 1: Esophageal stricture (EGD 1) Figure: Figure 2: Endoscopic appearance following 12mm dilation (EGD 2), crepe paper like mucosa in upper third of the esophagus"

Dermatology • Dermatopathology • Esophageal Squamous Cell Carcinoma • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Lichen Planus • Rheumatoid Arthritis • Squamous Cell Carcinoma

A Markov Cost-Effectiveness Analysis Evaluating the Downstream Impact of Post Flovent Pricing Variability for Swallowed Fluticasone in EoE (ACG 2026) - "Over 2.5 years, swallowed fluticasone under stable/base-case pricing conditions and budesonide slurry demonstrated comparable costs and effectiveness. Fluticasone base-case pricing was associated with total costs of $12,083 and 2.078 QALYs, compared with $12,777 and 2.086 QALYs for budesonide slurry. In contrast, a high-cost/variable fluticasone pricing scenario reflecting post-Flovent pricing instability and increased access-related nonadherence was associated with substantially higher costs ($22,946) despite similar effectiveness (2.069 QALYs)."

Cost effectiveness • HEOR • Pricing • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology

Behind the Rings:â¯Why Histology Is King in Lymphocytic Esophagitis (ACG 2026) - "She was maintained on her immunosuppression (abatacept) and a proton pump inhibitor (PPI), with plan for empiric dilation if dysphagia persists...She failed to improve on PPI and faced compliance and financial barriers, including insurance denial of oral budesonide suspension and non-adherence to fluticasone inhaler, resulting in persistent symptoms and is being switched to Dupilumab...Further studies are needed to elucidate risk factors and tailor guidelines specifically for LE. Figure: Schatzki ring in Case 2 on EGD Figure: Schatzki ring in Case 3 on EGD"

Breast Cancer • Diabetes • Dyspepsia • Eosinophilic Esophagitis • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Lupus • Metabolic Disorders • Solid Tumor • Systemic Lupus Erythematosus

Dupilumab vs Swallowed Topical Corticosteroids in Eosinophilic Esophagitis: A Real-World Propensity-Matched Analysis of Fibro-Stenotic Outcomes (ACG 2026) - "Patients were assigned to either a dupilumab cohort or a swallowed topical corticosteroid cohort (fluticasone, mometasone, or budesonide). After propensity matching, 1,568 patients were included in each cohort (mean age 36.1 ± 15.1 years; 58.7% male). Mean follow-up after matching was 402 days in the dupilumab cohort and 1,359 days in the swallowed topical corticosteroid cohort. Dupilumab therapy was associated with significantly lower rates of fibro-stenotic and symptomatic complications."

Clinical • Real-world • Real-world evidence • Allergic Rhinitis • Asthma • Atopic Dermatitis • Dermatitis • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology • Inflammation • Respiratory Diseases

A Case of Lymphocytic Esophagitis: Separate Entity Commonly Misdiagnosed as Eosinophilic Esophagitis (ACG 2026) - "We transitioned her to topical steroid therapy (fluticasone) with significant symptomatic improvement and scheduled her for repeat EGD for follow up...Further research is needed to establish clear diagnostic criteria and optimal treatment strategies. Figure: Endoscopic changes from lymphocytic esophagitis Figure: Endoscopic changes from lymphocytic esophagitis"

Clinical • Cardiovascular • Celiac Disease • Crohn's disease • Eosinophilic Esophagitis • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hypertension • Immunology • Inflammatory Bowel Disease • Rare Diseases

Beyond the Burn: Lymphocytic Esophagitis as a Hidden Driver of Fibrostenotic Dysphagia (ACG 2026) - "Although standardized guidelines are lacking, management options include swallowed topical corticosteroids (fluticasone or budesonide) to target the lymphocytic inflammatory profile, alongside aggressive mechanical dilation for stenotic disease...(B) Post-dilation visualization of a superficial mucosal tear with associated self-limited oozing Figure: High-power view of the proximal esophageal squamous mucosa demonstrating characteristic features of lymphocytic esophagitis. There is increased density of chronic inflammatory cells (lymphocytes) scattered throughout the epithelium, with marked prominence and clustering within a thickened basal layer [yellow arrow]"

Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Inflammation • Mucositis